Bayer's Portfolio Overhaul Is the Real Test of Its Re-Rating Case

Bayer shares are up 32% this year, but further gains hinge on a Missouri court approving its glyphosate settlement and the Apollo minority stake sale closing.

Bayer's stock has been on a tear this year, but the next leg higher depends less on momentum than on two unrelated events converging: a Missouri judge's signature and the closing of a minority stake sale. Everything else — pipeline wins, divestments, analyst upgrades — is noise until those two dominoes fall.

On Monday, Grünenthal disclosed plans to acquire the worldwide rights to Bayer's cancer drug Stivarga for up to EUR 375 million, with the deal expected to close in late 2026 or early 2027. The announcement lifted Bayer shares 1.9% to EUR 48.95, extending their year-to-date advance to 32%. It marked the latest step in a divestment campaign that management is running at pace to shore up financial flexibility.

Legal Certainty Is the Swing Factor

For all the operational progress, the market still grades Bayer through the lens of its U.S. glyphosate litigation. The company struck a comprehensive settlement in February worth up to USD 7.25 billion, payable over a maximum of 21 years, and in June the U.S. Supreme Court ruled 7-2 in its favor on federal product-safety preemption. Neither has closed the book.

The decisive criterion remains final judicial confirmation. Only once the Missouri Circuit Court's approval — following a hearing held just over a week ago — becomes legally binding does an open-ended litigation risk convert into a quantifiable financial liability. That shift is the precondition for investors to value the core business primarily on fundamental earnings metrics, such as the adjusted EBITDA range of EUR 9.6 billion to EUR 10.1 billion Bayer targets for full-year 2026.

Divestments and Pipeline Wins Build the Bull Case

Should the legal settlement hold, a durably positive scenario opens up — one in which the strategy of monetizing non-core assets while reinforcing the pharma pipeline pays off. More than a month ago, an agreement with Apollo over a minority stake in the reversible long-acting contraceptive business secured EUR 3.0 billion in equity for Bayer. Monday's Stivarga sale adds further cash to the balance sheet.

The innovation engine is running in parallel. The FDA granted approval on Friday for Kerendia in the Type-1 diabetes indication, according to media reports. In May, Bayer acquired U.S. biotech Perfuse Therapeutics for up to USD 2.45 billion, securing rights to a Phase II asset targeting glaucoma and diabetic retinopathy.

If Bayer can sustain this operational momentum and land at the upper end of its core earnings-per-share guidance of EUR 4.30 to EUR 4.90, the valuation discount to international peers should narrow meaningfully.

The Bear Case: Margin Drag and Late-Stage Legal Risk

The risk sits in a combination of operational inertia and delays to the legal breakthrough. Should the Missouri judge unexpectedly object to the negotiated settlement or demand revisions, uncertainty would flare up immediately, forcing market participants to once again price in unquantifiable provisions and liquidity risk.

If growth rates in the agriculture and pharma businesses stay at this subdued level, the portfolio overhaul risks fizzling out. Revenue lost to disposals such as Stivarga must be offset by new products — a transition period that can weigh on earnings power.

Debt Target Trimmed, Analysts Pile In

On the financial side, management recently adjusted expectations. The group lowered its net financial debt forecast for year-end 2026 to EUR 29 billion to EUR 30 billion, from a prior EUR 32 billion to EUR 33 billion. It simultaneously reaffirmed its existing earnings targets and, at a Crop Science investor event, its five-year goals.

Those interim steps drew a positive response from market watchers. On September 10, Deutsche Bank Research maintained its "Buy" rating on Bayer with a EUR 60 price target, citing the confirmed multi-year targets in the agriculture business. Two days earlier, Barclays had updated its view, raising its Bayer price target from EUR 60 to EUR 70 while keeping an "Overweight" rating.

The stock closed Friday at EUR 47.96, a daily loss of 2.3%, though still up 30% since the start of the year.

Two Milestones Set the Guardrails

As long as the market can trust that the U.S. settlement will be confirmed on schedule and the 2026 operating forecast holds, the foundation for a re-rating stays intact. A failed judicial approval or a marked deterioration in agriculture margins would instead rattle investor confidence and pressure the shares.

The next directional catalyst is the Missouri Circuit Court's pending decision on the Roundup settlement. At the same time, market observers are tracking the closing of the Apollo partnership, slated for the current third quarter of 2026. Only when both milestones are cleared will it become clear whether the path to a sustainable fundamental recovery is finally open.